An article on vivax malarial recurrences was highlighted in the "Global Malaria News" section of last week's MalariaWorld Newsletter. Below (in the next paragraph) is a relevant explanation concerning the article (http://theconversation.com/why-does-malaria-recur-how-pieces-of-the-puzz...):
WHO is undertaking a consultative process to solicit inputs into a prioritization framework for the research and development (R&D) of malaria health products. A draft report “Analysis of Malaria R&D Priorities” identifies five key challenges that represent threats or barriers to achieving the WHO Global Technical Strategy for Malaria 2016–2030 goals. This early copy of the report is being shared at a time when WHO is exploring how best to guide and support the development of priority solutions to meet public health needs.
WHO welcomes feedback on this draft report until 28 February 2019, including the correction of errors or omissions, updates to product development pipelines, and perspectives on the approach to prioritization.
FRANCE 24 brings you an in-depth investigation into the debate between those for and against this natural anti-malaria remedy, which appears as a threat to large pharmaceutical laboratories.
MESA co-hosting a critical global gathering in response to the latest disease reality and future innovation and financing needs
The MESA Alliance is set to co-host an invite-only scientific symposium entitled, “Innovate for Collective Impact to End Malaria”, on Friday, January 11, 2019, at the National Academy of Sciences in Washington, DC, USA. Its core objective is to frame a response to the 2018 World Malaria Report and to develop innovative approaches to collectively bridge critical issues in malaria eradication spanning research, financing, and implementation.
We are proud to inform you that MalariaWorld's Bart Knols has won the Marc Cornelissen Brightlands Award 2018 for his work in the fight against malaria.
Malaria is on the rise in more than 13 countries. And that is very scary!
This year's report shows that after an unprecedented period of success in global malaria control, progress has stalled. Data from 2015–2017 highlight that no significant progress in reducing global malaria cases was made in this period. There were an estimated 219 million cases and 435 000 related deaths in 2017.
The World malaria report 2018 draws on data from 91 countries and areas with ongoing malaria transmission. The information is supplemented by data from national household surveys and databases held by other organizations.
The most promising or the most frightening experiment in the fight against malaria: should or shouldn’t we use genetically modified mosquitoes to combat malaria?
TEXAS BIOMEDICAL RESEARCH INSTITUTE - PUBLIC RELEASE: 17-OCT-2018
More than 150 people have died from Ebola virus disease in 2018
San Antonio, Texas (October 17, 2018) -- Ebola virus is a continuing threat in Central and West Africa, with an outbreak currently taking place in the Democratic Republic of Congo. The disease kills up to 90% of the people who get infected, and more than 150 people have died from Ebola so far this year. The factors that determine who is susceptible to Ebola infection and who is not are still a mystery.
Silas Majambere, Mosquito Consulting
The amount of time that passes between a symptomatic vivax malarial episode and a subsequent recurrence has in the past often been regarded as an indication as to whether the recurrence is a relapse (hypnozoite origin) or a recrudescence (merozoite origin). It should be noted that in the light of new knowledge and understanding, the time factor is not a valid criterion. (Link to first paper). (Link to second paper).
This repository comprises a carefully selected set of more than 190,000 bibliographic records covering all aspects of research on malaria.
- Pilot trial shows suppository form of artesunate can slash severe malaria deaths
- Success down to drug formulation, better knowledge of disease also reported
- Large-scale rollout in well-functioning health systems could be ‘ground-breaking’
The French periodical PARIS MATCH published an extensive document on the fight against malaria with Artemisia annua and Artemisia afra. And the dubious role WHO plays.
We talk about asymptomatic, submicroscopic plasmodial infections as potentially being a threat to the elimination of malaria. This is, of course, partly because such infections are not normally treated; especially not in rural endemic areas where laboratory facilities are limited. An aggravation of the situation is when parasitaemias are so low that they cannot be detected by molecular diagnosis (where available) either. But obstacles to elimination are probably even greater than has been realized.
Progress in malaria elimination across the Asia-Pacific is at critical cross-roads, threatened by the spread of multidrug resistant falciparum malaria and continued transmission among marginalized and mobile populations living and working in conditions beyond the reach of traditional malaria control interventions.
As you probably do, I eagerly check MalariaWorld almost every day, and when I have something to contribute, post a blog or comment. But I am disappointed by the lack of responses to my contributions, or to those from all of you. How can we improve this?
Since almost 10,000 people are connected thru MalariaWorld, we might make real progress if we can all contribute. I want to end malaria sooner, not later. Do you agree?
Amiodarone which is used to control irregular heartbeat also has a protective effect in malaria. It triggers eryptosis and the clearance of malaria infected erythrocytes. In Plasmodium berghei infected mice amiodarone injections increased the survival. It is interesting to note that amiodarone is also active against other tropical diseases like Chagas or Leishmaniasis, both in vitro and in vivo, probably by disrupting the parasites' Ca(2+) homeostasis,
It is valuable and refreshing to see contributions to strategies for malaria suppression in Africa from other disciplines, such as economics. Killeen and Reed pointed out that the portfolio effect cushions mosquito populations and malaria transmission against vector control interventions.(Killeen GF, Reed TE. Malar J. 2018 Aug 10;17(1):291. doi: 10.1186/s12936-018-2441-z.) Thus it must be considered when planning a strategy for Africa.
Vaccines blocking the invasion of malaria sporozoites failed so far, after 30 years of efforts, millions spent, and disastrous human clinical trials. The efforts and the millions are now focused on vaccines blocking transmission by gametocytes. The results are not yet encouraging but the updated Malaria Vaccine Technology Roadmap foresees that there will be a TBV vaccine available in 2030. The update was necessary as the program launched by WHO in 2000 ( TDR/RBM/MAL/VAC/2000.1) has not yet progressed very far.
Published: July 18th 2018
Print ISBN: 978-1-78923-550-0
The two links below did not come up in the original "Comment" on a paper but should do so in this "Blog" version, which appears in full below. It was speculated in detail for the first time in two recent publications (particularly the second one) that in addition to a hypnozoite origin of relapse-like vivax recurrences, parasites in bone marrow might be a source. (Link to first paper). (Link to second paper).
In 2001 WHO posted a statement on their home page, without signatures, without references: « Due to the instability of artemisinin in raw materials of Artemisia annua L, the leaves need to be stored in cool conditions — preferably below 20°C. Most malaria endemic countries have warm climates and people generally lack access to refrigeration, so it is difficult for patients to keep artemisinin-containing tea bags under 20°C in their homes” A statement not substantiated by scientific papers. Cui bono?
Our associations immediately gathered available data which prove the contrary
“To end malaria there
is need for vision,
people to lead that
vision as seen when
the first person landed
on the moon.”
Don't miss out! Last chance to register!
Join us from 1-5th July 2018 in Melbourne, Australia for this unique multi-sector Congress.